Tarsus Pharmaceuticals, Inc.
TARS
주식 순위
#4599
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
주가
$71.43
시가총액
$3.34B
변동 (1일)
2.78%
변동 (1년)
0.34%
국가
US
거래 Tarsus Pharmaceuticals, Inc. (TARS)
카테고리
Healthcare
Tarsus Pharmaceuticals, Inc. (TARS)의 수익
Jun 2026 기준 수익 TTM: $-44.05M
Tarsus Pharmaceuticals, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-44.05M입니다. 2023년에 회사는 $-135.89M의 수익을 올렸으며 이는 2022년의 수익 $-62.10M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Tarsus Pharmaceuticals, Inc.의 수익 기록 (2018 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $-44.05M | -61.88% |
| 2024 | $-115.55M | -14.97% |
| 2023 | $-135.89M | 118.85% |
| 2022 | $-62.10M | 350.88% |
| 2021 | $-13.77M | -48.63% |
| 2020 | $-26.81M | 474.21% |
| 2019 | $-4.67M | 254.25% |
| 2018 | $-1.32M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | -12,073.99% |
US
|
|
| $-3.09B | 6,907.47% |
US
|
|
| $-4.02B | 9,016.74% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -4,527.96% |
NL
|
